ArticleCancer cell2020
Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia.
Open access · greenAbstract read
In one paragraph
Article in Cancer cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 126 papers.
0numbers the graph read from it
0cells of the map it votes in
126citing papers in PubMed
21.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
126 citing papers in PubMed, 189 citations in OpenAlex.
- Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemia.Cell reports. Medicine · 2026Article
- TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.Nature cancer · 2026Article
- Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.Blood neoplasia · 2026Article
- An immunocompetent bone marrow-on-a-chip model for studying human hematological malignancies and preclinical therapeutic screening.Nature protocols · 2026Review
- Deep learning based individualized cross-platform molecular subtype classification of B-lineage acute lymphoblastic leukemia.NPJ precision oncology · 2026Article
- ZNF184 negatively regulates HR repair and predicts poor prognosis in acute lymphoblastic leukemia.Nucleic acids research · 2026Article
- Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells.Nature biomedical engineering · 2026Article
- Article
- Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Altered immune and treatment response gene expression signatures among poverty-exposed children with B-ALL.bioRxiv : the preprint server for biology · 2026Article
- Low frequency and rare coding variants affect susceptibility and progression of childhood acute lymphoblastic leukemia.Cancer cell international · 2026Article
- Interplay between monocyte subsets and leukemic blasts shapes the immune microenvironment and sustains minimal residual disease in pediatric B-cell acute lymphoblastic leukemia.Frontiers in immunology · 2026Article
- Comprehensive omics-based classification system in adult patients with B-cell acute lymphoblastic leukemia.Molecular oncology · 2025Article
- Bioengineered immunocompetent preclinical trial-on-chip tool enables screening of CAR T cell therapy for leukaemia.Nature biomedical engineering · 2025Article
- "Monocytes in B-Cell Malignancies: Their Role in Disease Progression and Therapy Resistance".Current oncology reports · 2025Review
- Remodeling of the immune microenvironment is linked to adverse outcome in pediatric T cell acute lymphoblastic leukemia.Nature communications · 2025Article
- Inflammatory stromal and T cells mediate human bone marrow niche remodeling in clonal hematopoiesis and myelodysplasia.Nature communications · 2025Article
- Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment.Leukemia · 2025Article
- CD86, the double agent: Significance of CD86 expression in B-cell malignancies.International journal of cancer · 2025Review
- Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance.Journal for immunotherapy of cancer · 2025Article
66 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 3 institutions in 1 country.
Matthew T WitkowskiDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA. Electronic address: matthew.witkowski@nyulangone.org.
Igor DolgalevDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA; Applied Bioinformatics Laboratories, New York University School of Medicine, New York, NY 10016, USA.
Nikki A EvensenDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Chao MaDepartment of Mechanical and Aerospace Engineering, New York University, New York, NY 11202, USA; Department of Biomedical Engineering, New York University, New York, NY 11202, USA.
Tiffany ChambersDivision of Pediatric Hematology/Oncology, College of Medicine, Baylor University, Houston, TX 77030, USA.
Kathryn G RobertsDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Sheetal SreeramDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Yuling DaiDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Anastasia N TikhonovaDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Audrey LasryDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Chunxu QuDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Deqing PeiDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Cheng ChengDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Gabriel A RobbinsDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Joanna PierroDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
Shanmugapriya SelvarajDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Experimental Pathology Research Laboratory, New York University School of Medicine, New York, NY 10016, USA.
Valeria MezzanoDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Experimental Pathology Research Laboratory, New York University School of Medicine, New York, NY 10016, USA.
Marla DavesDivision of Pediatric Hematology/Oncology, College of Medicine, Baylor University, Houston, TX 77030, USA.
Philip J LupoDivision of Pediatric Hematology/Oncology, College of Medicine, Baylor University, Houston, TX 77030, USA.
Michael E ScheurerDivision of Pediatric Hematology/Oncology, College of Medicine, Baylor University, Houston, TX 77030, USA.
Cynthia A LoomisDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Experimental Pathology Research Laboratory, New York University School of Medicine, New York, NY 10016, USA.
Charles G MullighanDepartment of Pathology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Weiqiang ChenDepartment of Mechanical and Aerospace Engineering, New York University, New York, NY 11202, USA; Department of Biomedical Engineering, New York University, New York, NY 11202, USA.
Karen R RabinDivision of Pediatric Hematology/Oncology, College of Medicine, Baylor University, Houston, TX 77030, USA.
Aristotelis TsirigosDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA; Applied Bioinformatics Laboratories, New York University School of Medicine, New York, NY 10016, USA.
William L CarrollDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA. Electronic address: william.carroll@nyulangone.org.
Iannis AifantisDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA; Laura & Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA. Electronic address: ioannis.aifantis@nyulangone.org.
New York University · USBaylor University · USSt. Jude Children's Research Hospital · US
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MThe impact of changes in chromatin architecture on cancer phenotypes and tumor progressionP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jane Amanda Skok · 2019 to 2026
$17.0MThe cohesin complex as a tumor suppressor in myeloid leukemiaR01CA216421 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, LEVINE, ROSS L · 2017 to 2021
$2.5MMechanisms of enhancer regulation in leukemiaR01CA228135 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS · 2019 to 2023
$2.5MMapping cancer micro-environments for acute leukemiaR01CA202025 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, SCHWAB, SUSAN RUTH · 2016 to 2020
$2.3MPost-translational control of cancer cell stress response and metastasisR01CA202027 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI AIFANTIS, IANNIS, HERNANDO, EVA · 2016 to 2020
$2.3MMultispectral imaging & analysis of intact tissue sections w/ the Perkin Elmer VectraS10OD021747 · OD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI LOOMIS, CYNTHIA A · 2016 to 2016
$359kNCI NIH HHS P01 CA229086NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA202025NCI NIH HHS R01 CA202027NCI NIH HHS R01 CA216421NCI NIH HHS R01 CA228135NIH HHS S10 OD021747
Abstract
A subset of B cell acute lymphoblastic leukemia (B-ALL) patients will relapse and succumb to therapy-resistant disease. The bone marrow microenvironment may support B-ALL progression and treatment evasion. Utilizing single-cell approaches, we demonstrate B-ALL bone marrow immune microenvironment remodeling upon disease initiation and subsequent re-emergence during conventional chemotherapy. We uncover a role for non-classical monocytes in B-ALL survival, and demonstrate monocyte abundance at B-ALL diagnosis is predictive of pediatric and adult B-ALL patient survival. We show that human B-ALL blasts alter a vascularized microenvironment promoting monocytic differentiation, while depleting leukemia-associated monocytes in B-ALL animal models prolongs disease remission in vivo. Our profiling of the B-ALL immune microenvironment identifies extrinsic regulators of B-ALL survival supporting new immune-based therapeutic approaches for high-risk B-ALL treatment.
Indexed as
AdolescentAdultAnimalsAntineoplastic AgentsBone Marrow TransplantationCase-Control StudiesChildChild, PreschoolFemaleHumansInfantMaleMice, Inbred C57BLMonocytesNeoplasm Recurrence, LocalPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsProteomeacute lymphoblastic leukemiachemotherapyimmune microenvironmentmonocytesrelapsesingle cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.